Targets › HTR2C
32 programs from 32 companies in 116 trials: 49 Phase 2, 29 Phase 4, 20 Phase 1, 18 Phase 3; Psychiatry, Other, Neurology; next expected readout Nov 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). (UniProt, P28335)
Open in Phaseline: the race on HTR2C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| John D. Dingell VA Medical Center | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Sleep Apnea | Dec 2026 |
| Tongji University | trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Depressed Insomniac Co-morbid Patients | Dec 2026 |
| The University of Texas Health Science Center at San Antonio | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Parkinson's Disease Psychosis | Feb 2027 |
| Beth Israel Deaconess Medical Center | Lorcaserin Serotonin 2c (5-HT2c) receptor agonist | HTR2C | Phase 4 | Obesity | Jun 2027 |
| The Chaim Sheba Medical Center | risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Velocardiofacial Syndrome | Aug 2027 |
| Centre for Addiction and Mental Health | Risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Schizophrenia and Related Disorders | Sep 2027 |
| Northwell Health | risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Psychosis; Acute; Schizophenia Disorder | Dec 2029 |
| Massachusetts General Hospital | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Bipolar I Disorder | Feb 2030 |
| VA Office of Research and Development | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Sleep Disordered Breathing | Jun 2030 |
| Madigan Army Medical Center | Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 4 | Low Back Pain | – |
| Chinese University of Hong Kong | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Mild Cognitive Impairment | – |
| Zogenix | Fenfluramine Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile Spasm | Nov 2027 |
| Foundation for Advancing Veterans' Health Research | Quetiapine Fumarate Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 3 | Mild Traumatic Brain Injury | Jun 2028 |
| UCB BIOSCIENCES | fenfluramine hydrochloride Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | Rett Syndrome | Feb 2029 |
| University of Minnesota | Qsymia Phentermine/topiramate extended-release combination; sympathomimetic amine and carbonic an | ADRA1A, HTR2C | Phase 3 | Healthy Volunteers | Oct 2030 |
| University of North Carolina, Chapel Hill | Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | Acute Stress Reaction | Nov 2026 |
| Washington State University | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Stimulant Use Disorder | Dec 2026 |
| University of Michigan | Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | High Tone Pelvic Floor Dysfunction | Dec 2026 |
| University of Trieste | mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | RETT Syndrome With Proven MECP2 Mutation | Dec 2026 |
| Boryung Pharmaceutical | Olanzapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy … | May 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 2 | Insomnia Chronic | Jul 2027 |
| M.D. Anderson Cancer Center | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Advanced Cancer | Dec 2027 |
| Tonix Pharmaceuticals | Cyclobenzaprine Hydrochloride (TNX-102) Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | Major Depressive Episode (MDE); Pharmakokinetic | Feb 2028 |
| Lone Baandrup | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 2 | Psychiatric Disorders | Feb 2029 |
| Centre Hospitalier St Anne | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 2 | Depression - Major Depressive Disorder | Dec 2029 |
| University of California, Irvine | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Glioma of Brain | Dec 2030 |
| University of California, San Diego | Phentermine-Topiramate Sympathomimetic amine and gamma-aminobutyric acid modulator for weight loss | HTR2C, GABA | Phase 2 | Colitis, Ulcerative | – |
| Md. Moktadirul Hoque Shuvo | Trifluoperazine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Functional Dyspepsia | – |
| University of Arizona | Ziprasidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 1 | Schizophrenia | Feb 2027 |
| Verinder Sharma | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 1 | Postpartum Depression | – |
Obstructive Sleep Apnea (4) Schizophrenia (3) Multiple Myeloma (3) Advanced Cancer (2) Schizophrenia and Related Disorders (2) Advanced Malignant Solid Neoplasm (2) Prostate Cancer (2) Multiple Sclerosis (2) Cardiac Amyloidosis (2) Ulcerative Colitis (2) Alcohol Use Disorder (AUD) (2) Pediatric HIV Infection (2)
small molecule (30), protein or peptide (1)
UCB BIOSCIENCES (1) M.D. Anderson Cancer Center (1) The Chaim Sheba Medical Center (1) Verinder Sharma (1) Washington State University (1) Boryung Pharmaceutical (1) University of Arizona (1) Northwell Health (1) University of North Carolina, Chapel Hill (1) University of California, Irvine (1) Brigham and Women's Hospital (1) Foundation for Advancing Veterans' Health Research (1) Md. Moktadirul Hoque Shuvo (1) University of Michigan (1) Centre hospitalier de l'Université de Montréal (CHUM) (1) University of Minnesota (1) John D. Dingell VA Medical Center (1) Zogenix (1) Madigan Army Medical Center (1) University of Pennsylvania (1)
HTR2A (27) DRD2 (11) SLC6A4 (8) ADRA2A (5) ADRA2C (5) ADRA2B (5) HTR1D (2) SIGMAR1 (2) DRD3 (2) DRD4 (2) OPRM1 (2) SLC5A2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.